Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital, Beijing, 100029, China.
Department of Pulmonary and Critical Care Medicine, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China.
Sci Rep. 2019 Feb 4;9(1):1254. doi: 10.1038/s41598-018-36611-w.
In China, there are an estimated 30 million people with asthma, a condition that remains poorly controlled in many patients. The INITIAL study (NCT02143739) was a 12-week, multicentre, prospective, observational study comprising 45 centres across Northern and Southern China that aimed to assess asthma severity among newly diagnosed patients as well as their prescribed medications and response to treatment. The primary objective was to evaluate asthma severity using Global Initiative for Asthma (GINA) 2006 research criteria. Secondary objectives included the distribution of asthma medication by GINA severity category and evaluation of GINA 2012-defined control levels. Medications were prescribed as per usual clinical practice. At baseline, among 4491 patients, 3.9%, 12.0%, 22.6% and 61.6% had intermittent, mild persistent, moderate persistent and severe persistent asthma, respectively. Inhaled corticosteroid/long-acting β agonist was the most common initial therapy in 90.2% of patients. GINA 2012-defined controlled asthma levels increased in all groups, rising from 6.1% at baseline to 43.0%, 53.8% and 67.8% at Weeks 4, 8 and 12, respectively. Most patients presented with severe persistent asthma. Newly diagnosed patients with asthma could benefit from at least 3 months of regular treatment followed by long-term pharmacological management.
在中国,大约有 3000 万人患有哮喘,许多患者的病情控制仍不理想。INITIAL 研究(NCT02143739)是一项为期 12 周、多中心、前瞻性、观察性研究,共纳入中国北方和南方的 45 个中心,旨在评估新诊断的哮喘患者的严重程度以及他们的处方药物和治疗反应。主要目标是使用全球哮喘倡议(GINA)2006 年研究标准评估哮喘严重程度。次要目标包括根据 GINA 严重程度类别分布哮喘药物和评估 GINA 2012 定义的控制水平。药物的使用是按照常规临床实践来开具的。在基线时,在 4491 名患者中,分别有 3.9%、12.0%、22.6%和 61.6%的患者患有间歇性、轻度持续性、中度持续性和重度持续性哮喘。在 90.2%的患者中,吸入皮质激素/长效β激动剂是最常见的初始治疗药物。根据 GINA 2012 定义,所有组别的控制哮喘水平都有所提高,从基线时的 6.1%分别上升到第 4、8 和 12 周时的 43.0%、53.8%和 67.8%。大多数患者都表现出严重持续性哮喘。新诊断的哮喘患者可能受益于至少 3 个月的常规治疗,然后进行长期的药物治疗管理。